• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非钙化导管原位癌(DCIS):升级为浸润性癌的发生率和预测因素。

Noncalcified Ductal Carcinoma In Situ (DCIS): Rate and Predictors of Upgrade to Invasive Carcinoma.

机构信息

Massachusetts General Hospital/Department of Radiology, 55 Fruit Street, WAC 240, Boston, MA 02114.

Massachusetts General Hospital/Department of Surgery, Boston, MA.

出版信息

Acad Radiol. 2021 Mar;28(3):e71-e76. doi: 10.1016/j.acra.2020.02.011. Epub 2020 Mar 26.

DOI:10.1016/j.acra.2020.02.011
PMID:32222328
Abstract

RATIONALE AND OBJECTIVES

To determine the upgrade rate of noncalcified ductal carcinoma in situ (DCIS) and features that are associated with risk of upgrade to invasive disease at surgery.

MATERIALS AND METHODS

A retrospective review was conducted of consecutive women who were diagnosed with noncalcified DCIS from January 2007 to December 2016. Patient demographics, imaging findings, biopsy pathology results, and surgical outcomes were reviewed. The unpaired t test, chi-square test, and Fisher's exact test were used to compare features between the cases of DCIS that did and did not upgrade to invasive carcinoma at surgery.

RESULTS

Over a 10-year period, 78 women (mean age 62 years, range 30-88 years) were diagnosed with noncalcified DCIS. Two-thirds (67.9%, 53/78) of cases were detected on screening mammography, and 15.4% (12/78) of diagnoses were made after presentation with an area of palpable concern. The most common mammographic presentations of noncalcified DCIS were mass (51.3%, 40/78) and asymmetry (30.8%, 24/78). Seventeen cases (21.8%, 17/78) were upgraded to invasive ductal carcinoma (IDC) at surgery. Features associated with upgrade risk included older patient age (68.1 versus 60.3 years, OR 1.08, p < 0.01) and family history of breast cancer in a first-degree relative (41.2% [7/17] versus 16.4% [10/61], OR 3.57, p = 0.03).

CONCLUSION

In our study cohort, the upgrade rate of noncalcified DCIS to IDC at surgery is 21.8%. Upgrade risk is associated with older patient age and family history of breast cancer in a first-degree relative.

摘要

背景与目的

本研究旨在明确非钙化性导管原位癌(DCIS)的升级率,以及与手术时升级为浸润性疾病相关的特征。

材料与方法

回顾性分析 2007 年 1 月至 2016 年 12 月期间连续诊断为非钙化性 DCIS 的女性患者。评估患者的人口统计学特征、影像学表现、活检病理结果和手术结局。采用独立样本 t 检验、卡方检验和 Fisher 确切概率法比较 DCIS 患者中未升级为浸润性癌与升级为浸润性癌患者的特征差异。

结果

在 10 年期间,共诊断出 78 例非钙化性 DCIS 患者(平均年龄 62 岁,范围 30-88 岁)。67.9%(53/78)的病例在筛查性乳房 X 线摄影中发现,15.4%(12/78)的病例因可触及的病灶就诊。非钙化性 DCIS 的最常见的 X 线表现为肿块(51.3%,40/78)和不对称(30.8%,24/78)。17 例(21.8%,17/78)患者在手术时升级为浸润性导管癌(IDC)。与升级风险相关的特征包括患者年龄较大(68.1 岁比 60.3 岁,OR 1.08,p<0.01)和一级亲属乳腺癌家族史(41.2%[7/17]比 16.4%[10/61],OR 3.57,p=0.03)。

结论

在本研究队列中,非钙化性 DCIS 手术时升级为 IDC 的比例为 21.8%。升级风险与患者年龄较大和一级亲属乳腺癌家族史相关。

相似文献

1
Noncalcified Ductal Carcinoma In Situ (DCIS): Rate and Predictors of Upgrade to Invasive Carcinoma.非钙化导管原位癌(DCIS):升级为浸润性癌的发生率和预测因素。
Acad Radiol. 2021 Mar;28(3):e71-e76. doi: 10.1016/j.acra.2020.02.011. Epub 2020 Mar 26.
2
Ductal Carcinoma In Situ (DCIS) at Breast MRI: Predictors of Upgrade to Invasive Carcinoma.乳腺 MRI 中的导管原位癌(DCIS):升级为浸润性癌的预测因素。
Acad Radiol. 2020 Oct;27(10):1394-1399. doi: 10.1016/j.acra.2019.09.025. Epub 2019 Nov 4.
3
Ductal carcinoma in situ on digital mammography versus digital breast tomosynthesis: rates and predictors of pathologic upgrade.数字乳腺钼靶摄影与数字乳腺断层合成摄影中导管原位癌的检出率及其病理升级的预测因素。
Eur Radiol. 2020 Nov;30(11):6089-6098. doi: 10.1007/s00330-020-07021-2. Epub 2020 Jun 26.
4
Predicting Upgrade of Ductal Carcinoma In Situ to Invasive Breast Cancer at Surgery With Ultrafast Imaging.利用超快成像预测导管原位癌在手术中升级为浸润性乳腺癌。
AJR Am J Roentgenol. 2023 Jul;221(1):34-43. doi: 10.2214/AJR.22.28698. Epub 2023 Feb 8.
5
Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study.导管原位癌的筛查检测及随后发生的浸润性间隔期乳腺癌:一项基于人群的回顾性研究。
Lancet Oncol. 2016 Jan;17(1):109-14. doi: 10.1016/S1470-2045(15)00446-5. Epub 2015 Dec 5.
6
Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women.比较韩国女性的乳腺密度和临床因素与导管原位癌和浸润性导管乳腺癌的关联。
BMC Cancer. 2017 Dec 5;17(1):821. doi: 10.1186/s12885-017-3841-0.
7
The role of MRI and clinicopathologic features in predicting the invasive component of biopsy-confirmed ductal carcinoma in situ.MRI 与临床病理特征在预测经活检证实的导管原位癌中浸润性成分的作用。
BMC Med Imaging. 2020 Aug 12;20(1):95. doi: 10.1186/s12880-020-00494-z.
8
AI analytics can be used as imaging biomarkers for predicting invasive upgrade of ductal carcinoma in situ.人工智能分析可作为影像学生物标志物,用于预测原位导管癌的浸润性进展。
Insights Imaging. 2024 Apr 5;15(1):100. doi: 10.1186/s13244-024-01673-0.
9
Digital Mammography Has Persistently Increased High-Grade and Overall DCIS Detection Without Altering Upgrade Rate.数字乳腺 X 线摄影术持续提高高级别和总体 DCIS 检出率,而不改变升级率。
AJR Am J Roentgenol. 2021 Apr;216(4):912-918. doi: 10.2214/AJR.20.23314. Epub 2021 Feb 17.
10
Trends in detection of invasive cancer and ductal carcinoma in situ at biennial screening mammography in Spain: a retrospective cohort study.西班牙两年一次的筛查性乳房 X 光检查中浸润性癌和导管原位癌检出率的变化趋势:一项回顾性队列研究。
PLoS One. 2013 Dec 23;8(12):e83121. doi: 10.1371/journal.pone.0083121. eCollection 2013.

引用本文的文献

1
Risk Factors for Positive Resection Margins Following Breast-Conserving Surgery.保乳手术后切缘阳性的危险因素。
Cureus. 2024 Dec 26;16(12):e76406. doi: 10.7759/cureus.76406. eCollection 2024 Dec.
2
Presurgical Upgrade Prediction of DCIS to Invasive Ductal Carcinoma Using Time-dependent Deep Learning Models with DCE MRI.使用基于 DCE MRI 的时变深度学习模型对 DCIS 进行术前升级预测为浸润性导管癌。
Radiol Artif Intell. 2024 Sep;6(5):e230348. doi: 10.1148/ryai.230348.
3
Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates.
选择性省略导管原位癌乳房切除术的前哨淋巴结活检术:确定合格的候选者。
Breast Cancer Res. 2024 Apr 12;26(1):65. doi: 10.1186/s13058-024-01816-7.
4
Prediction of Surgical Upstaging Risk of Ductal Carcinoma In Situ Using Machine Learning Models.使用机器学习模型预测导管原位癌的手术分期升级风险
J Breast Imaging. 2023 Oct 17;5(6):695-702. doi: 10.1093/jbi/wbad071. eCollection 2023 Nov-Dec.
5
Ipsilateral tumor recurrence risk in women with ductal carcinoma in situ: application of the Van Nuys Prognostic Index and the Memorial Sloan Kettering Cancer Center nomogram.同侧肿瘤复发风险在患有导管原位癌的女性中:Van Nuys 预后指数和 Memorial Sloan Kettering 癌症中心列线图的应用。
Breast Cancer Res Treat. 2023 Nov;202(1):185-190. doi: 10.1007/s10549-023-07036-5. Epub 2023 Jul 30.
6
Does pre-operative breast MRI have an impact on surgical outcomes in high-grade DCIS?术前乳腺 MRI 是否会影响高级别 DCIS 的手术结果?
Br J Radiol. 2022 Sep 1;95(1138):20220306. doi: 10.1259/bjr.20220306. Epub 2022 Jul 25.
7
Clinicopathological Features of 166 Cases of Invasive Ductal Breast Carcinoma and Effect of Primary Tumor Location on Prognosis after Modified Radical Mastectomy.166例浸润性导管癌的临床病理特征及原发肿瘤部位对改良根治术后预后的影响
Emerg Med Int. 2022 Jun 18;2022:3158956. doi: 10.1155/2022/3158956. eCollection 2022.
8
Is conservative management of ductal carcinoma in situ risky?导管原位癌的保守治疗有风险吗?
NPJ Breast Cancer. 2022 Apr 28;8(1):55. doi: 10.1038/s41523-022-00420-2.
9
Sentinel lymph node biopsy in patients with ductal carcinoma in situ: systematic review and meta-analysis.前哨淋巴结活检在导管原位癌患者中的应用:系统评价和荟萃分析。
BJS Open. 2022 Mar 8;6(2). doi: 10.1093/bjsopen/zrac022.
10
Imaging and pathologic features of non-calcified ductal carcinoma in situ: can sonography predict upgrade?非钙化型导管原位癌的影像学及病理学特征:超声检查能预测升级吗?
Br J Radiol. 2022 Feb 1;95(1130):20211013. doi: 10.1259/bjr.20211013. Epub 2021 Dec 21.